Translational Immunology – From Target to Therapy IV
Translational Immunology – International experts in immunology meet in Würzburg, where Rudolf Virchow laid the foundation for modern pathology
Harnessing the immune system to treat cancer patients has been a big leap forward in cancer therapy of the past years. Clinical approval of new immunotherapies preventing immune escape in cancer patients build on scientific advances of the past decades. This novel approach is encouraging, but more patients should benefit by advancing and refining immunotherapies and the accompanying diagnostics. These exciting developments and their current limitations but also advances in autoimmune, inflammatory and infectious diseases were the focus of this year’s 4th Else-Kröner-Symposium “Translational Immunology – From Target to Therapy IV”. Pioneers in the field from all over the world convened for two days in Würzburg. Expert scientists presented and discussed newest preclinical and basic research data and recent results from clinical trials. Particularly, immunologists at the meeting focussed on how to overcome remaining challenges and to move the field forward. Again, we organized this year’s international Else-Kröner-Symposium at Würzburg’s Gartenpavillon at the Juliusspital. In this historic venue Rudolf Virchow laid important foundations for modern pathology. The meeting from May 4-5, 2017 provided an excellent opportunity for young scientists to present and discuss their own research with international experts in the fields of cancer immunotherapy, inflammation, autoimmune and infectious diseases.
The Translational Immunology – From Target to Therapy IV conference was generously supported by the Else Kröner-Fresenius-Stiftung.